LARGE B-CELL LYMPHOMA (LBCL)

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…

This study tests a combination of four drugs (polatuzumab vedotin, zanubrutinib, lenalidomide, and glofitamab) in 30 older patients (70+) newly diagnosed with large B-cell lymphoma who are too frail for standard chemo. The goal is to see if this gentler regimen can control the ca…

This early-stage trial tests whether adding a drug called CLS-015 to standard CAR-T cell therapy can help people with large B-cell lymphoma whose disease is stable or getting worse. CLS-015 works by breaking down NETs, which are immune-trapping webs that may block CAR-T cells. Th…

This study is testing a more affordable version of CAR-T cell therapy for people with relapsed or hard-to-treat large B-cell lymphoma. The treatment uses the patient's own immune cells, modified to attack cancer cells. The goal is to see if this academic-made therapy works as wel…

This study tests a treatment called CD19 CAR-T therapy for people newly diagnosed with a fast-growing type of blood cancer called high-risk large B-cell lymphoma. The therapy uses a patient's own immune cells, modified to better attack cancer cells. The main goal is to see how ma…